Business Wire

DE-CSC

17.11.2020 13:02:04 CET | Business Wire | Press release

Share
Holiday Shopping Warning: Simple Typos Can Lead Consumers and Brands to Online Fraud, Counterfeit Goods, and Cyber Crime

CSC , a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division warning consumers that simple URL typos could lead to significant online fraud, counterfeit goods, and cyber crime during the holiday shopping season. The company identified and analyzed registered domain typos (misspellings) associated with the 10 largest online shopping brands in the world and found that over 70% of the 1,553 registered domain typos appear to be owned by third parties.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005233/en/

According to CSC’s new research , these third-party owned domains receive over five million visitors annually. In addition, 40% of these domains are using domain privacy services to mask or hide their ownership and identity, and close to 48% are configured with MX (mail) records that can be used for phishing and to intercept email. In its blog, CSC offers tips to both brand owners and consumers to protect themselves against fraudulent web properties and content.

A deep dive of the top 100 most visited typo domains shows they are being used in this manner:

  • 38% are pointing to advertising-related and pay-per-click web content, which can be used to spread malware via domain parking services
  • 27% had no live web content, yet 37% were configured to send and receive email with MX records
  • 15% were engaged in affiliate referrals, which means the brand owner could be targeted for unauthorized affiliate activity resulting in loss of revenue
  • 12% were pointing at shopping-related web content, which indicates that consumers could engage with nefarious retailers selling counterfeit goods while brand owners lose revenue
  • 8% were pointing toward malicious web content e.g., malware

During the holiday shopping season, just one hour of downtime can cost a business over $500,000 in lost revenue*. Despite this, many global eCommerce and shopping companies are still lacking basic domain security measures that could prevent this from happening. For instance, only 16% of the top 500 global eCommerce and shopping domains leverage domain name system (DNS) hosting redundancy, which could secure their online presence from a distributed denial of service (DDoS) attacks. In addition, only 18% use registry locks that prevent DNS hijacking attacks that could redirect consumers to alternate websites. Lastly, 40% of retailers do not use enterprise-class domain registrars. This is partially explained by the fact that 40% of the observed domains still rely on retail registrars that typically don’t provide advanced domain security features.

“ In light of the global pandemic, both consumers and leading brands have embraced online shopping as we head into the 2020 holiday season. As such, we wanted to call attention to how brands and consumers are at increased risk for a multitude of threat vectors associated with online fraud, counterfeits, revenue leakage and many other cyber criminal activities this year,” says Ihab Shraim, chief technology officer for CSC. “As evidenced by the sheer number of mail-in votes in the U.S. election, consumers are looking for safe alternatives to in-person interactions, and it’s important for brands to not only provide those digital channels, but also ensure they are secure from online threat vectors.”

“We’re delighted that companies like CSC are advocating for companies and online brands to put the necessary security protocols in place to protect not only their brand reputation, but their consumers, from online fraud and cyber crime,” says Daniel Eliot, director of Education and Strategic Initiatives at the National Cyber Security Alliance (NCSA). “The NCSA's mission is to educate consumers and businesses about these credible risks, and the importance of using recommended cyber security best practices. CSC’s research is also an important part of advocating for consumers, and showing the pervasive risk of these cyber attacks and fraudulent domains.”

Additional resources:

*gremlin.com/ecommerce-cost-of-downtime/

About CSC

CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system, digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/CSCSince1899/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye